WO2015081188A1 - Composition pharmaceutique contenant un composé d'oméga-(arylsulfonyl)alkylnitrile - Google Patents

Composition pharmaceutique contenant un composé d'oméga-(arylsulfonyl)alkylnitrile Download PDF

Info

Publication number
WO2015081188A1
WO2015081188A1 PCT/US2014/067597 US2014067597W WO2015081188A1 WO 2015081188 A1 WO2015081188 A1 WO 2015081188A1 US 2014067597 W US2014067597 W US 2014067597W WO 2015081188 A1 WO2015081188 A1 WO 2015081188A1
Authority
WO
WIPO (PCT)
Prior art keywords
pain
inflammation
pharmaceutical composition
compound
inflammatory
Prior art date
Application number
PCT/US2014/067597
Other languages
English (en)
Inventor
Joseph P. St. Laurent
Gerald S. Jones
David M. Bresse
Original Assignee
Olatec Industries Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olatec Industries Llc filed Critical Olatec Industries Llc
Publication of WO2015081188A1 publication Critical patent/WO2015081188A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton

Definitions

  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a
  • the present invention also relates to methods of using the compound for treating inflammation or inflammatory-related disorders and pain.
  • Inflammation is a process by which microbes or tissue injury induce the release of cytokines and chemokmes from various cell types producing increased blood vessel penneahility, upregulation of endothelial receptors, and thus increased egress of various cells of the innate and adaptive immune system which enter surrounding tissue and grossly produce the classical picture of inflammation, i.e. redness, swelling, heat and pain.
  • Inflammation is a localized reaction of live tissue due to an injury, which may be caused by various endogenous and exogenous factors.
  • the exogenous factors include physical, chemical, and biological factors.
  • the endogenous factors include inflammatory mediators, antigens, and antibodies. Endogenous factors often develop under the influence of an exogenous damage. An inflammatory reaction is often followed by an altered structure and penetrability of the cel lular membrane. Endogenous factors, such as medi ators and antigens define the nature and type of an inflammatory reaction, especially its course in the zone of injury. In the case where tissue damage is limited to the creation of mediators, an acute form of inflammation develops.
  • immunologic reactions are also involved in the process, through the interaction of antigens, antibodies, and autoantigens, a long-term inflammatory process will develop.
  • Various exogenous agents for example, infection, injury, radiation, also provide the course of inflammatory process on a molecular level by damaging cellular membranes which initiate biochemical reactions.
  • pain can be divided into three types: nociceptive, neuropathic, and mix-type.
  • Nociceptive pain is the term for pain that is detected by specialized sensory nerves called nociceptors. These nerves are located throughout the soft tissues, such as muscles and skin, as well as the internal organs. There are two types of nociceptive pain: somatic pain and visceral pain. Visceral pain comes from the internal organs. Deep somatic pain is initiated by stimulation of nociceptors in ligaments, tendons, bones, blood vessels, fasciae and muscles, and is dull, aching, poorly localized pain. Examples include sprains and broken bones. Superficial pain is initiated by activation of nociceptors in the skin or other superficial tissue, and is sharp, well-defined and clearly located.
  • Examples of inj uries that produce superficial somatic pain include minor wounds and minor (first degree) burns.
  • Nociceptive pain is usually short in duration and end when the damage recov ers.
  • Examples of nociceptive pain include postoperative pain, sprains, bone fractures, burns, bumps, bruises, and inflammatory pain .
  • Neuropathic pain is pain caused by damage or disease that affects the somatosensory system. Neuropathic pain is originated from spontaneous ectopic neuron discharge in the nervous system either in central or in peripheral. Because the underlying etiologies are usually irreversible, most neuropathic pain are chronic pain. Most people describe neuropathic pain as shooting, burning, tingling, lancinating, electric shock qualities, numbness, and persistent allodynia. The nomenclature of neuropathic pain is based on the site of initiating nervous system with the etiology; for examples, central post-stroke pain, diabetes peripheral neuropathy, post-herpetic (or post-shingles) neuralgia, terminal cancer pain, phantom limb pain.
  • Mix-type pain is featured by the coexistence of both nociceptive and neuropathic pain.
  • muscle pain trigger central or peripheral neuron sensitization leading to chronic low back pain, migraine, and myofacial pain.
  • Connective tissues are subjected to a constant barrage of stress and injur ⁇ '.
  • Acute or chronic impacts and the natural progression of various degenerative diseases all produce painful inflammation in joint regions, such as the neck, back, arms, hips, ankles and feet. These afflictions are common and often debilitating.
  • composition should be economic and easy to manufacture, and the method should be effective and have no significant side effects.
  • the present invention is directed to a pharmaceutical composition
  • a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a 3-(arylsulfonyl)propaiienitrile compound or a pharmaceutically acceptable salt or solvate thereof.
  • the compound is at least 90% pure (w/w).
  • the present invention is also directed to a method for treating inflammation, inflammatory-related disorders, and pain.
  • the method comprises the step of administering a 3-(arylsuifonyl)propanenitrile compound or a pharmaceutically acceptable salt thereof to a subject in need thereof.
  • the pharmaceutical composition comprising the active compound can be applied by any accepted mode of administration including topical, oral, and parenteral (such as intravenous, intramuscular, subcutaneous or rectal). Topical administration and oral administration are preferred.
  • Alkyl refers to groups of from 1 to 12 carbon atoms, either straight chained or branched, preferably from 1 to 8 carbon atoms, and more preferably 1 to 6 carbon atoms.
  • Aryl refers to an unsaturated aromatic carbocyclic group of from 6 to 14 carbon atoms inclusively having a single ring (e.g., phenyl) or multiple condensed rings (e.g., naphthyl or anthryl). Preferred aryls include phenyl, naphthyi and the like.
  • Arylalkyl refers to aryl-alkyl- groups preferably having from 1 to 6 carbon atoms in the alkyl moiety and from 6 to 10 carbon atoms in the aryl moiety. Such arylalkyl groups are exemplified by benzyl, phenethyl and the like.
  • Cycloalkyl refers to cyclic alkyl groups of from 3 to 12 carbon atoms having a single cyclic ring or multiple condensed rings which can be optionally substituted with from 1 to 3 alkyl groups.
  • Such cycloalkyl groups include, by way of example, single ring structures such as cyclopropyi, cyciobutyl, cyclopentyl, cyclooetyl, l-methylcyclopropyl, 2-methyicyclopentyl, 2- methyicyciooctyi, and the like, or multiple ring structures such as adamantyl, and the like.
  • “Pharmaceutically acceptable salts,” as used herein, are salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects.
  • Pharmaceutically acceptable salt forms include various crystalline polymorphs as well as the amorphous form of the different salts.
  • the pharmaceutically acceptable salts can be formed with metal or organic counterfoils and include, but are not limited to, alkali metal salts such as sodium or potassium; alkaline earth metal salts such as magnesium or calcium; and ammonium or tetraalkyl ammonium salts, i.e., NX 4 + (wherein X is CM). ro ⁇ (Arylsulfonyl)lalkylnitriles
  • M ⁇ (a] isiiliOnyl)alkyinitriies (or ⁇ - (aTylsulfonyi)alkanenitriles) of Formula I, or a pharmaceutically acceptably salt or solvate thereof, are effective for treating inflammation, inflammatory-related disorders, and pain.
  • Rj and R 7 are independently H, straight-chain alkyl, branched alkyl, cycloalkyl, and arylalk l;
  • R 2 - Re are independently selected from the group consisting of H, C : ( ,alkyl (e.g., methyl, ethyl, n-propyl, i-propyl, n -butyl, i-butyl, sec-butyl, t-butyl), cycloalkyl (e.g., cyciopentyl, cyclohexyl), phenyl, substituted phenyl, arylalkyl (e.g. benzyl), halogen (e.g. fluoro, chloro, bromo, iodo), cyano, carboxy, carboxyamido, acetyl, hydroxyl,
  • ,alkyl e.g., methyl, ethyl, n-propyl, i-propyl, n -butyl, i-butyl, sec-butyl, t-butyl
  • R. 2 and R 3 , l s and R 4 , or R 3 and R are connected so as to produce a fused, bicyclic ring structure, e.g., naphthyl;
  • R?-R are independently H, C ⁇ alkyl, C 1-6 alkoxy, amino, or halogen.
  • R4-R5 and the phenyl ring form a naphthyl, optionally substituted with Cj-6 alkyl, amino, or halogen.
  • Preferred ⁇ (arylsuifonyl)aikyimtriles useful for the present invention are 3- (arylsulfonyl)propan.enitrile compounds of formula II, or a pharmaceutically acceptably salt or solvate thereof:
  • Preferred useful for the present invention also include
  • R4 and Rs are independently , C h alky!, Q-galkoxy, amino, or halogen; or R4 and R 5 are connected so as to produce a fused, bicyclic ring structure, e.g., naphthyl.
  • 05-(Arylsulfonyl)aikyliiitriles can be prepared by alkylating the appropriate thiophenoi or thiophenolate anion, or naphthalenethiol or naphthalenethiolate anion with ⁇ - bromoalkylnitrile, followed by oxidation of the products with hydrogen peroxide or other oxidizing agents (Scientia Sinica 1974, 17, 743-751). Alternatively, o
  • arylsulfonyialkylnitriles can be prepared by alkylation of the requisite aryl sulfuric acid sodium salts, the latter of which are commerci ally available or can be made by known synthetic procedures.
  • the present invention provides pharmaceutical compositions comprising one or more pharmaceutically acceptable carriers and an active compound -(arylsulfonyl)alkylnitriles of Formula I or 3-(arylsdfonyl)piOpanenitrile of Formula ⁇ , or a pharmaceutically acceptable salt, or solvate thereof.
  • the active compound or its pharmaceutically acceptable salt or solvate in the pharmaceutical compositions in general is in an amount of about 0.01-20%, or 0.05-20%, or 0.1-20%, or 0.2-15%, or 0.5-10%, or 1-5% (w/w) for a topical formulation; about 0.1-5%) for an injectable formulation, 0.1-5% for a patch formulation, about 1-90% for a tablet formulation, and 1-100% for a capsule formulation.
  • the active compound is incorporated (solubilized or suspended) into any acceptable carrier, including creams, gels, lotions, ointments or other types of vehicles that can stabilize the active compound and deliver it to the affected area by topical applications.
  • the pharmaceutical composition can be in a dosage form such as tablets, capsules, granules, fine granules, powders, syrups, suppositories, injectable solutions, patches, or the like.
  • the above pharmaceutical composition can be prepared by conventional methods.
  • Pharmaceutically acceptable carriers which are inactive ingredients, can be selected by those skil led in the art using conventional criteria.
  • Pharmaceutically acceptable carriers include, but are not limited to, non-aqueous based solutions, suspensions, emulsions, microemulsions, micellar solutions, gels, and ointments.
  • the pharmaceutically acceptable carriers may also contain ingredients that include, but are not limited to, saline and aqueous electrolyte solutions; ionic and nonionic osmotic agents such as sodium chloride, potassium chloride, glycerol, and dextrose; pH adjusters and buffers such as salts of hydroxide, phosphate, citrate, acetate, borate; and trolamine; antioxidants such as salts, acids and/or bases of bisulfite, sulfite, metabisulfite, thiosulfite, ascorbic acid, acetyl cysteine, cysteine, glutathione, butylated hydroxyanisole, butylated hydroxytoluene, tocopherols, and ascorbyl palmitate; surfactants such as lecithin, phospholipids, including but not limited to
  • hydroxypropyl methylcellulose and their salts petroleum derivatives such as mineral oil and white petrolatum; fats such as lanolin, peanut oil, palm oil, soybean oil; mono-, di-, and triglycerides; polymers of acrylic acid such as carboxypolymethylene gel, and
  • hydrophobically modified cross-linked acrylate copolymer comprising polysaccharides such as dextrans and glycosaminoglycans such as sodium hyaluronate.
  • pharmaceutically acceptable carriers may be preserved against bacterial contamination using well-known preservatives, these include, but are not limited to, benzaikonium chloride, ethylenediaminetetraacetic acid and its salts, benzethonium chloride, chlorhexidine, chlorobutanol, methylparaben, thimerosal, and phenylethyl alcohol, or may be formulated as a non-preserved formulation for either single or multiple use.
  • a tablet formulation or a capsule formulation of the active compound may contain other excipients that have no bioactivitv and no reaction with the active compound.
  • Excipients of a tablet or a capsule may include fillers, binders, lubricants and glidants, disintegrators, wetting agents, and release rate modifiers. Binders promote the adhesion of particles of the formulation and are important for a tablet formulation.
  • Examples of exeipients of a tablet or a capsule include, but not limited to, carboxymethylcel ose, cellulose, ethylcellulose, hydroxypropylmethylcellulose, methylcellulose, karaya gum, starch, tragacanth gum, gelatin, magnesium stearate, titanium dioxide , poly(acrylic acid), and polyvinylpyrrolidone.
  • a tablet formulation may contain inactive ingredients such as colloidal silicon dioxide, crospovidone, hypromellose, magnesium stearate, microcrystailine cellulose, polyethylene glycol, sodium starch glycolate, and/or titanium dioxide.
  • a capsule formulation may contain inactive ingredients such as gelatin, magnesium stearate, and/or titanium dioxide.
  • a patch formulation of the active compound may comprise some inactive ingredients such as 1,3-butylene glycol, dihydroxyaluminum aminoacetate, disodium edetate, D- sorbitol, gelatin, kaolin, methylparaben, polysorbate 80, povidone, propylene glycol,
  • inactive ingredients such as 1,3-butylene glycol, dihydroxyaluminum aminoacetate, disodium edetate, D- sorbitol, gelatin, kaolin, methylparaben, polysorbate 80, povidone, propylene glycol,
  • a patch formulation may also contain skin permeability enhancer such as lactate esters (e.g., lauryl lactate) or di ethylene glycol monoethyl ether.
  • Topical formulations including the acti ve compound can be in a form of gel, cream, lotion, liquid, emulsion, ointment, spray, solution, and suspension.
  • the inactive ingredients in the topical formulations for example include, but not limited to, lauryl lactate
  • emollient permeation enhancer diethylene glycol monoethyl ether (emollient permeation enhancer), DMSO (solubility enhancer), silicone elastomer (rheology/texture modifier), caprylic/capric triglyceride, (emollient), octisalate, (emollient UV filter), silicone fluid
  • Inactive ingredients that can be used with the active compounds to form a gel formulation for example include, but not limited to, diethylene glycol monoethyl ether, phenyl trimethicone, silica silylate, acrylates/C 10-30 alky 1 acrylate crosspolymer, and water.
  • Inactive ingredients that can be used with the active compounds to form a cream formulation for example include, but not limited to, mineral oil, vegetable oil, petrolatum, cetostearyl alcohol, cetearyl alcohol, sodium lauryl sulfate, sodium polyacrylate, propylene glycol, dicaprylyl carbonate, tocopherol, cetearyl isononanoate, ceteareth-20, glyceryl monostearate, glycerin, POE cetyl/stearyl ether, cetyl palmitate, C 12.15 alky! benzoate, phenyl trimethicone, octisalate, tocopheryl acetate, pa thenol, cyclopentasi loxane and dimethiconol, a d water.
  • lauryl lactate (for example, at about 0.1 -10%, or about 0.2-5%, or about 0.5-5%) is included in the topical gel formulation.
  • Lauryl lactate is considered safe for topical administration.
  • Lauryl lactate is qualified for human use within pharmaceutical and cosmetic products.
  • Lauryl lactate when used in a topical formulation enhances the permeability of the compound.
  • Preferably lauryl lactate is purified to achieve > 90%, preferably > 95% purity; the high purity mitigates the presence of hydrolytic and oxidative agents.
  • DMSO at 0.1-20%, or 0.5-10% (w/w) in the formulation provides suitable solubility of the active compound.
  • dietbylene glycol monoethyl ether is included in the topical gel formulation.
  • Inflammation is a process and a state of tissue pathology resulting from activation and continuation of activity of the innate and acquired components of the immune system.
  • the arachidonic acid cascade and cytokine production and action in cell to cell interactions are critical components of immune activation and respon se, which lead to inflammation.
  • Arachidonic acid resides in many cell membranes. When arachidonic acids are cleaved from the membranes, it can produce many of the known eicosinoids including prostaglandins and leucotrienes, which are known pro-inflammatory entities.
  • the active compounds are effective in inhibiting pro-inflammatory cytokine release (e.g., IL- ⁇ ⁇ , IL-1 receptor antagonist, IL-6, TNFa, IL-4 and IFNy) from human peripheral blood mononuclear cells in vitro.
  • the active compound is antiinflammatory when applied topically in the mouse ear swelling model, in which the inflammation is induced by arachidonic acid.
  • the present invention is directed to a method of treating inflammation and/or pain.
  • the active compound can be used as is, or it can be administered in the form of a pharmaceutical composition that additionally contains a pharmaceuticall acceptable carrier.
  • the method comprises the steps of first identifying a subject suffering from inflammation and/or pain, and administering to the subject the active compound, in an amount effective to treat inflammation and/or pain.
  • An effective amount is the amount effective to treat a disease by ameliorating the pathological condition or reducing the symptoms of the disease.
  • the method reduces or alleviates the symptoms associated with inflammation.
  • the present invention provides a method to treat localized manifestations of inflammation characterized by acute or chronic swelling, pain, redness, increased
  • the present invention provides a method to alleviate the symptoms of pain regardl ess of the cause of the pain.
  • the general term "pain" treatable by the present method includes nociceptive, neuropathic, and mix-type.
  • the present invention reduces pain of varying severity, i.e. mild, moderate and severe pain; acute and chronic pain.
  • the present invention is effective in treating joint pain, muscle pain, tendon pain, bum pain, and pain caused by inflammation.
  • the present invention is useful in treating inflammation and/or pain associated in a musculoskeletal system or on the skin.
  • the highly innervated, musculoskeletal and skin systems have a high capacity for demonstration of pain.
  • the highly innervated, musculoskeletal and skin systems have a high capacity for demonstration of pain.
  • musculoskeletal system has a high capacity for tissue swelling, and the skin has a high capacity for redness, swelling, and heat.
  • the degree of tissue damage is frequently magnified out of proportion to the resulting inflammatory response.
  • merely firm stroking will cause release of the cytokines, IL-1 and TNF.
  • the present invention provides a method for treating inflammation and/or pain associated with inflammatory skeletal or muscular diseases or conditions.
  • the method comprises the steps of identifying a subject in need thereof, and administering to the subject the active compound, in an amount effective to treat inflammation and/or pain.
  • the skeletal or muscular diseases or conditions include musculoskeletal sprains, musculoskeletal strains, tendonopathy, peripheral radiculopathy, arthritis, osteoarthritis, joint degenerative disease, polymyalgia rheumatica, juvenile arthritis, gout, ankylosing spondylitis, psoriatic arthritis, systemic lupus erythematosus, costochondritis, tendonitis, bursitis, such as the common lateral epicondylitis (tennis elbow), medial epicondylitis (pitchers elbow) and trochanteric bursitis, temporomandibular joint syndrome, and fibromyalgia.
  • the present invention is directed to a method of treating inflammation and/or pain associated gout.
  • Gout is a chronic inflammatory disease that is characterized by recurrent, sudden, and severe attacks of acute inflammation (redness and tenderness) and pain at the joints, often at the base of the big toe. Gout is caused by elevated levels of uric acid in the blood. Gout is a type of arthritis. Some people may develop chronic gout, which is also called gouty arthritis.
  • the present invention provides a method for treating inflammation and/or pain associated with inflammatory skin diseases such as dermatitis, psoriasis, and acne.
  • the method comprises the steps of identifying a subject in need thereof, and administering to the subject the active compound, in an amount effective to treat inflammation and/or pain.
  • the present invention further provides a method for treating inflammatory skin diseases such as dermatitis, psoriasis, and acne (Acne vulgaris).
  • the method comprises the steps of identifying a subject in need thereof, and administering to the subject the active compound, in an amount effective to reduce or eliminate the symptoms of the disease.
  • Skin is highly reactive to environmental stimuli and the epidermal component of keratinocytes is a very ric source of both arachidonic acid and pro-inflammatory cytokines of IL-1 and TNF.
  • Dermatitis also called eczema
  • Dermatitis is generic inflammation of the skin. Specific types of dermatitis include atopic, contact, nummular, and photo-induced.
  • Contact dermatitis is an inflammatory condition of the skin either of irritant exposure to the skin without specific adaptive immunologic pathogenesis or of allergic sensitization and subsequent exposure of the skin to the sensitizing allergen with specific adaptive immunologic pathogenesis. Both involve innate and acquired immune system response including arachidonic acid and cytokine components that initiate and propagate the disease through ceil to ceil messaging by eicosanoid and/or cytokine moieties produced by epidermal cells, macrophages, dendritic ceils, neutrophils, eosinophils, and various T and B
  • Contact dermatitis may be either acute or chronic.
  • the acute forms are pruritic with erythema, edema, and micro or macrovesiculation in the areas of skin contact by the initiating factor.
  • the chronic forms are pruritic with milder erythema, scaling, lichenification, and possibly Assuring particularly on the hands.
  • Atopic dermatitis is a genetical ly determined di sease that is part of the broader disease complex of atopy that includes asthma, hay fever, and atopic dermatitis. Many individuals with atopic dermatitis have various mutations of the filaggrin gene that codes for an important epidermal structural protein that when defective, results in abnormal barrier function of the epidermis.
  • the altered barrier allows exposure to multiple environmental allergens that are first recognized by innate immune responses involving arachidonic acid and eicosanoids and recruitment of eosinophils, mast ceils, and other inflammatory cells that initiate an acute responses of itch, erythema, and subsequent scratching and additionally activate the adaptive immune responses that involve inflammation by lymphocytes predominantly of a TH 2 derivation and activity.
  • Atopic dermatitis is responsive to a number of cytokine inhibitors such as cyclosporine, and tacrolimus.
  • Acne vulgaris a progressively inflammatory disorder of the pilosebaceous follicular unit especially of the face and upper chest and back is a very common disease of both males and females after initiation of puberty, and in females even prior to adrenal gland maturity.
  • This consequent dilation of the pore and the changed composition of sebum at puberty facilitate colonization of the follicle by Propionibacterium acnes bacilli that produce enzymes to degrade the triglycerides in sebum to free fatty acids that leak through the follicle into the dermis and incite arachidonic acid pathways of eicosanoid production and subsequent initiation of inflammation.
  • the bacilli also initiate chemokine production that attracts further inflammatory cells to the area and consequent cytokine production and action to continue and amplify inflammation.
  • initiation and propagation of progressive inflammation in the microcomedo produces the evolution to the several hallmark lesions of inflammatory acne, papule, pustule, nodule, and cyst.
  • the present invention is useful to treat common acne, comedonic acne, papulopustule acne,
  • papuiocomedonic acne nodulocystic acne, acne conglobata, cheloid acne of the nape of the neck, recurrent miliary acne, necrotic acne, neonatal acne, occupational acne, acne rosacea, senile acne, solar acne or acne medicamentosa.
  • Rosacea is a chronic condition characterized by facial erythema and sometimes pimples.
  • Rosacea typically begins as redness on the central face across the cheeks, nose, or forehead, but can also less commonly affect the neck, chest, ears, and scalp. In some cases, additional symptoms, such as semi-permanent redness, telangiectasia (dilation of superficial blood vessels on the face), red domed papules (small humps) and pustules, red gritty eyes, burning and stinging sensations, and in some advanced cases, a red lobulated nose (rhinophyma), may develop. There are 3 subtypes of rosacea that affect the skin: erythematoteiaiigieetatic rosacea, papulopustular rosacea, and phymatous rosacea.
  • o (Arylsulfonyl)alkymitriles whic are effective in inhibiting arachidonic acid induced inflammation and in inhibiting the release of pro-inflammatory cytokine, are effective to treat inflammation and/or pain associated with psoriasis, acne, rosacea, and dermatitis, such as contact dermatitis, and atopic dermatitis.
  • to-(Aiyisuifony])alkylnitriies are effective in treating atopic coveratitis and alleviating one or more symptoms selected from the group consisting of erythema, induration ,
  • a (Arylsulfonyl)alky[mtriles are effective in treating psoriasis and alleviating erythema, scaling, and/or thickness of the psoriasis lesions.
  • oj-(Aiylsulfonyi)alkylnitriles are effective in treating acne and alleviating acne lesions selected from the groups consisting of closed comedones, papules, pustules, nodules, and cysts.
  • M ⁇ (AtylsuiiOnyl)aikyinitriies are effective in treating rosacea and alleviating one or more symptoms selected from the group consisting of erythema, telangiectasia, red domed pap ules and pustules, red gritty eyes, and burning and stinging sensations.
  • the pharmaceutical composition of the present invention can be applied by local administration and systemic administration.
  • Local administration includes topical administration.
  • Systemic administration includes oral, parenteral (such as intravenous, intramuscular, subcutaneous or rectal), and other systemic routes of administration.
  • the active compound first reaches plasma and then distributes into target tissues.
  • Topical administration and oral admin stration are preferred routes of administration for the present invention.
  • Dosing of th e composition can vary based on t he extent of the injur ⁇ ' and eac patient's individual response.
  • plasma concentrations of active compounds delivered can vary; but are generally lxlO ⁇ l0 -lxlCP moles/liter, and preferably 1 ⁇ 1( 8 -1 ⁇ 10 moles/liter.
  • the composition is applied topically onto the affected area and nibbed into it.
  • the composition is topically applied at least 1 or 2 times a day, or 3 to 4 times per day, depending on the medical issue and the disease pathology being chronic or acute.
  • the topical composition comprises about 0.01-20%, or 0.05-20%, or 0.1.-20%, or 0.2- 15%, 0.5-10, or 1-5 % (w/w) of the active compound.
  • the topical composition compri ses about 1 or 5 % (w/w) of the active compound.
  • 0,2-85 mL, typically 0.2-10 mL, of the topical composition is applied to the individual per dose.
  • the active compound passes through skin and is delivered to the site of discomfort.
  • the pharmaceutical composition is administrated orally to the subject.
  • the dosage for oral administration is generally 0.5-100, or 1-50, and preferably 1-10, 1-5, or 5-50 rng/kg/day, depending on the patient's condition.
  • the active compound can be applied orally to an adult human at. 20-1000 mg/dosage, 20-500 mg/dosage, 100-800 mg/dosage, or 200-600 mg/dosage, 1-4 times a day, depends on the patient's condition.
  • the pharmaceutical composition is administrated subcutaneously to the subject.
  • the dosage for subcutaneous administration is generally 0.3-20, and preferably 0.3-3 mg/kg/day.
  • the present invention is useful in treating a mammal subject, such, as humans, horses, and dogs.
  • the present invention is particularly useful in treating humans.
  • 3-(4- ethoxyphenyi)sulfonylpropionitrile can be synthesized by alkylation of 4- methoxythiophenol with 3-bromopropionitrile under basic conditions, followed by peroxide oxidation of the intermediate sulfide.
  • 3-(3,4-Dichlorophenyl)sulfonylpropiomtrile can be synthesized by the alkylation of sodium (3,4-dichloropheriyi)sulfi.riate with 3-bromopropionitrile or by the alkylation of 3,4- dichlorothiophenol with 3-bromopropionitrile under phase transfer conditions, followed by peroxide oxidation of the intermediate sulfide.
  • Active compounds include 3-(arylsuifonyl)propanenitriles, such as 3- (pheiiylsuifony l)propioiiitrile, 3 - [(4-methylpheiiyl)sulfonyl]propionitriie, 3 -(naphthalene-!- suifonyl)-propionitrile, 3-[(4-chlorophenyl.)sulfonyi]propionitrile, which are purchased from Aldrich Rare Chemical Collection. Active compounds also include 3-(4- methoxyphenyl)sulfonylpropionitrile (Example 1) and 3-(3,4- dichlorophenyl)sulfonylpropionitrile (Example 2).
  • Tables 3-5 exemplify three cream formulations containing an active compound.
  • Active compounds include 3-(arylsulfonyl)propanenitriles, such as 3-
  • cetearyi alcohol ceteareth-20 3-5%
  • test compounds indomethacin (positive control), and vehicle were evaluated for anti-inflammatory activity in a topical arachidonic acid-induced ear swelling model in mice.
  • Arachidonic Acid 0.5 mg in 20 ⁇ of acetone:etlianol/l : l
  • Test compounds and vehicle, as listed in Table 1 were similarly applied 30 minutes before and 15 minutes after arachidonic acid application.
  • the thickness of the right ear and the left ear was measured and the difference calculated as an indication of the inflammation in the right ear.
  • Ear swelling was measured by a Dyer model micrometer gauge at 60 and 90 minutes after arachidonic acid application as an index of inflammation.
  • Percent inhibition was calculated according to the formula: Ic - It/Ic x 100, where Ic and It refers to increase of ear thickness (mm) in control and treated mice, respectively.
  • ANOVA and Dunnett's test were employed to ascertain significant difference between vehicle control and treated groups. Significance is set at P ⁇ 0.05 level. The results measured at 90 minutes after arachidonic acid application are summarized in Table 6.
  • the tested compounds all resulted in a significant inhibition (20-44%) in the ear swelling induced by arachidonic acid, relative to that in the vehicle-treated group.
  • the differences between treated mice and vehicle-treated mice were determined to be statistically significant (p-value by t-test was ⁇ 0.05).
  • dichlorophenyl)sulfonylpropionitrile prepared from Examples 1 and 2, were test compounds in this experiment.
  • test compounds indomethacin (positive control), and vehicle were evaluated for anti-inflammatory activity in a topical arachidonic acid-induced ear swelling model in mice.
  • mice weighing 22 ⁇ 2 g were used and randomly divided; the test compound and vehicle control had 10 mice, and indomethacin had 5 mice.
  • Arachidonic Acid (0.5 mg in 20 ⁇ of acetone :ethanol/l : ! ) was applied topically to the anterior and posterior surfaces of the right ear of each mouse. Test substances and vehicle, as listed in Table 4 were similarly applied 30 min before and 15 min after arachidonic acid application. The thickness of the right ear and the left ear was measured and the difference calculated as an indication of the inflammation in the right ear. Ear swelling was measured by a Dyer model micrometer gauge at 60 and 90 minutes after arachidonic acid application as an index of inflammation.
  • Percent inhibition was calculated according to the formula: Ic - It/Ic x 100, where Ic and It refers to increase of ear thickness (mm) in control and treated mice, respectively.
  • ANOVA and Durmett's test were employed to ascertain significant difference between vehicle control and treated groups. Significance is set at P ⁇ 0.05 level. The results measured at 90 minutes after arachidonic acid application are summarized in Table 7.
  • 3-[(4-Methylphenyl)sulfonyl]propionitrile was suspended in vehicle (1% Twee 80 in water) to 3 mg/mL.
  • vehicle 1% Twee 80 in water
  • the test compound, dexamethasone (positive control in vehicle), and vehicle were orally administered to mice and evaluated for anti-inflammatory activity in the topical arachidonic acid induced ear swelling model in mice.
  • mice Male ICR derived mice weighing 22 ⁇ 2 g were used in this experiment. 10 mice were used for each group (active compound, positive control, and vehicle). Ail animals were maintained in a controlled temperature (22-24°C) and humidity (60% - 70%) environment with 12-hour light/dark cycles for at least one week prior to use.
  • Arachidonic acid (0.5 mg in 20 uL acetone) was applied topically onto the anterior and posterior surfaces of the right ear of test animals to induce inflammation.
  • Active compound in vehicle (10 mL/kg) and vehicle (10 mL/kg, 30 mg/kg) was orally administered by gavage 1 hour before arachidonic acid, whereas dexamethasone was orally administered by gavage 3 hour before arachidonic acid challenge.
  • the thickness of the right ear and the left ear was measured and the difference calculated as an indication of the inflammation in the right ear.
  • the active compounds (3-(arylsulfonyl)propanenitriles) are tested for their inhibitory effects on in vitro cytokine release from human peripheral blood mononuclear ceils
  • PBMCs PBMCs secretion of cytokines by PBMCs plays a significant role in the inflammatory response.
  • PBMCs are stimulated to secrete cytokines using the mitogens lipopolysaccharide and concanavalm A (ConA).
  • ConA mitogens lipopolysaccharide
  • Lipopolysaccharide at 50pg/mL is used to stimulate the release of interleukin IL- ⁇ , IL-6 and tumor necrosis factor TNFa.
  • ConA at 20 ug/mL is used to stimulate the release of IL-4 and ConA at 5 ( ug/mL is used to stimulate interferon IFNy.
  • the corticosteroid dexamethasone 100 nM is used as a positive control.
  • the supernatants are assayed for the cytokines using the Luminex Bead kit.
  • the percent inhibition of IL-1 ⁇ , IL-6, TNFa, IL-4 and IFNy by the active compounds and the positive compound are calculated. The results demonstrate that the active compound has an inhibitory effect on cytokines involved in the inflammatory process.
  • 3-(Aryisuifonyl)propanenifriles are prepared as a gel formulation according to Example 3 or as a cream formulation according to Example 4.
  • Test materials, 3- (arylsulfonyi)propanenitriles in gel formulation ( 1 -5%), indomethacin (positive control), and vehicle (gel formulation without active compound) are evaluated for anti-inflammatory and analgesic activity in the rat carrageenan-induced paw inflammation model.
  • Rats are used in the experiment.
  • Carrageenan (0.1 mL of a 1% suspension) is injected subcutaneously into the left hind paw to induce inflammation.
  • Test material (1-5%) or vehicle gel is applied to the paw topically at volumes of 0.05, 0.1 0.15 or 2.0 mL, after 1.5, 2.5, and 3.5 hours following the carrageenan administration.
  • Indomethacin is given orally at 5 mg/kg, 1 hour prior to carrageenan administration.
  • the degree of inflammation is determined using a plethysmograpb to measure paw volume.
  • Analgesia is detennined by measuring paw withdrawal to a mechanical stimulus using von Frey filaments.
  • Test materials are expected to have anti-inflammatory and/or analgesic properties as measured by a significant decrease in paw volume and/or a significant increase in mechanical pressure needed to elicit paw withdrawal, respectively, as compared to the vehicle control.
  • 3-(Arylsulfonyl)propanenitri.les are prepared as a gel formulation according to Example 3 or as a cream formulation according to Example 4. Active compounds in a gel or cream formulation (1-5%), morphine (positive control), and vehicle (gel formulation without active compound), are evaluated for analgesic activity in the rat hot plate model.
  • Rats are used in the experiment. Test material (1-5%) or vehicle gel is applied to the paw topically at volumes of 0.05, 0.1 0.15 or 2,0 mL. One hour later the rat is placed on a 55°C hot plate, and the time to lick the paw is measured . The positive control, morphine, is given orally at 30 mg/kg, 1 hour prior to hot plate testing. Test materials are expected to have analgesic properties as measured by a significant increase in time to licking as compared to the vehicle control (t-test, p ⁇ 0.05).
  • CFA Complete Freund's Adjuvant
  • the intensity of the light is adjusted with average group baseline latency from 12 to 14 sec (pre-CFA) and a cut-off latency of 20 sec imposed.
  • the latency to withdrawal is obtained for each rat and defined as the heat pain threshold. Twenty four hours after CFA injection, rats are pre-selected (with clear presence of thermal hyperalgesia) for experimentation only if the latency to withdrawal is less than 75% of baseline.
  • 3-(ArylsulfonyI)piopanenitriles are prepared as a gel formulation according to Example 3 or as a cream formulation according to Example 4. Active compounds in a gel or cream formulation (1-5%), active compounds in DMSO, morphine (positive control, p.o., 20 mg/kg), topical vehicle (gel formulation without an active compound), and oral vehicle (DMSO) are evaluated for analgesic activity in the formalin model.
  • Test substance or vehicle is either administered oral ly (50, 100, or 500 rng/kg in D MSO), or topically ( 1-5% gel formulation) to the pl antar surface of the hind paw, at 60 minutes before the level of thermal hyperalgesia is again measured (post-treatment). Mean ⁇ SEM of thermal paw withdrawal time is calculated. Unpaired Student's t test is applied for compari son the values of post-treatment between test substance treated group and vehicle control group. Positive activity is considered at P ⁇ 0.05.
  • Formalin test is a model of continuous pain resulting from formalin-induced tissue injury. Nociceptive and inflammatory pain is induced by injection of a dilute formalin solution into the paw, resulting in nocifensive behavior including paw flinching.
  • the formalin model encompasses inflammatory, neurogenic, and central mechanism of pain. The early phase of pain (from 0 to about 10 minutes) is due to nociceptive mechanism and the late phase of pain (from 10-40 minutes) is due to a combination of inflammatory pain and nociceptive mechanism. Pain behavior is assessed using manual paw licking measurements. The end points of the study are the number of paw licking events. (Hunskaar et al., Pain, 30: 103-114, 1987; Li et al., Molecular Pain, 6:11 , 2010)
  • mice per group are used in the study. mmediately prior to testing (at time 0), mice are restrained in a cloth and injected with 20 ⁇ _- of a 5% formalin solution,
  • test compounds are subcutaneously into the dorsal surface of the left hind paw.
  • Vehicle control (DMSO) and test compounds 3-(arylsulfonyl)propanenitriles (in DMSO) are administered by oral gavage to mice.
  • the amounts of test compounds are 50, 200, or 500 mg/kg per dose.
  • Positive control morphine in saline is administered by subcutaneous injection at 8 mg/kg to mice, immediately before formalin injection and testing at time zero.
  • mice The number of licking events at different time points post formalin injection of vehicle control, morphine-treated, and test compound-treated mice are plotted in 5 minute intervals.
  • the numbers of licking events per minute are calculated between 0-10 minutes and 10-40 mmutes for vehicle, positive control, and test compound. A statistically significant reduction of licking event per minute is an indication that the test compound is effective in treating acute nociceptive pain (early phase) or inflammatory nociceptive pain (late phase).
  • Peripheral nerve lesions may generate a syndrome comprising, in addition to spontaneous pain, exaggerated responses to light touch (tactile allodynia).
  • Chronic constriction injury model is a neuropathic pain model.
  • Constriction of the sciatic nerve produces nerve injury and unilateral neuropathic pain.
  • Rats are pre-selected for experimentation only if the pain threshold 7-14 days after nerve ligation (pre -treatment) is reduced by 10 grams of force relative to the response of the individual paw before nerve ligation (pre-ligation), namely, with clear presence of allodynia.
  • 3-(Aiyisuifonyl)propanenitriies are prepared as a gel formulation according to Example 3 or as a cream fommlation according to Example 4.
  • 3 ⁇ (Arylsulfonyl)propanenitnles are also prepared in DMSO (50, 200, or 500 mg/kg) for oral administration.
  • Test compounds in a gel or cream formulation (1 -5%), test compounds in oral formulation (DMSO), morphine (positive control, p.o., 20 mg/kg), topical vehicle (gel formulation without an active compound), and oral vehicle (DMSO) are evaluated.
  • Test compound or vehicle is either administered orally (50, 200, or 500 mg/kg) or topically (1-5% gel formulation) to the plantar surface of the left hind paw.
  • the mechanical ailodynia test is performed 30 min before (pre-treatment) and 1 and 3 hours after a single dose of test compound or vehicle (post treatment). Paw withdraw thresholds of control and tested compounds are measured.
  • Active compounds 3-(phenylsuitbnyl)propioiiitriie, 3-[(4- methylphenyl)siilibnyl]propionitriie, 3-(naphthalene-2-sulfonyi)-propionitrile, 3 ⁇ [(4- chlorophenyl)sulfonyl]propionitrile, 3-(4-meth.oxyphenyl)sulfonylpropionitrile and 3 ⁇ (3,4 ⁇ dichlorophenyi)sulfonylpropionitrile are eac suspended in DMSO.
  • Vehicle control (DMSO) and each active compound are administered by oral gavage to mice with a volume of 5 mL kg.
  • the active compounds are each administered at a dosage of 50-500 mg/kg in dimethyl sulfoxide (DMSO).
  • mice There are 5 mice per group, with a total of 10 knees injected. On Day 1,
  • C57BL6mice are dosed (50, 200, or 500 mg/kg/dose) with active compounds or vehicle twice on Hours 0 and 12.
  • mice are dosed with active compounds or vehicle on Hour 24, then injected intra-articuiarly with 180 ⁇ g of zymosan (6 uL) into both knee joints on Hour 25, and then dosed a second time on Hour 36 with each active compound or vehicle.
  • mice are again dosed with each active compound or vehicle on Hour 48.
  • Two hour post- dosing on Hour 50 knees are scored for edema, synovial tissue is collected for measurement of cytokine levels, and knee joints are processed for histopathology for analysis of inflammatory immune ceil influx into the joint.
  • Macroscopic joint swelling is assessed on ail knees after the skin is removed using a scoring system ranging from 0 to 3, with 0 being no swelling and 3 being severe swelling.
  • Synovial tissue is taken from 5 knees for measurement of mouse mterieukin- ⁇ , interleukin-6, and mterleukm-l receptor antagonist levels. The remaining 5 knees are processed for microscopic pathology for assessment of cellular influx into the site of inflammation.
  • Results for each group are presented as mean ⁇ standard error of mean and statistical evaluation is performed. Treatment with active compounds are expected to result in decreased inflammation as measured by a decrease in joint swelling, decrease in cytokine levels and decrease influx of inflammatory cells to the site of inflammation.
  • MSU onosodium urate mono hydrate
  • Vehicle control (DMSO) and each active compound are administered by oral gavage to mice with a volume of 5 mL/kg.
  • the active compounds are each administered at a dosage of 50-500 mg/kg in DMSO.
  • mice There are 5 mice per group, with a total of 10 knees injected.
  • C57BL6 mice are dosed (50, 200, or 500 mg/kg/dose) with active compounds or vehicle twice on Flours 0 and 12.
  • mice are dosed with active compounds or vehicle on Hour 24, then injected intra-articularly with with MSU crystals (300 ag) and CI 8:0 FFA (200 ⁇ )(10 uL) on Hour 25.
  • Hour 28 Three hours later (Hour 28), knees are scored for edema, synovial tissue is collected for measurement of cytokine levels, and knee joints are processed for
  • Macroscopic joint swelling is assessed on all knees after the skin is removed using a scoring system ranging from 0 to 3, with 0 being no swelling and 3 being severe swelling.
  • Synovial tissue is taken from 5 knees for measurement of mouse interieukiii- ⁇ ⁇ , interleukin-6, and interleukin-1 receptor antagonist levels. The remaining 5 knees are processed for microscopic pathology for assessment of cellular influx into the site of inflammation.
  • Results for each group are presented as mean ⁇ standard error of mean and statistical evaluation is performed.
  • Treatment with active compounds are expected to result in decreased inflammation as measured by a decrease in joint swelling, decrease in cytokine levels and decrease influx of inflammatory ceils to the site of inflammation.
  • osteoarthritis of the knee as a well-established paradigm for other musculoskeletal disorders.
  • Topical Formulation 3-(Arylsulfonyl)propanenitriles are prepared as a gel formulation according to Example 3 or as a cream formulation according to Example 4. Active compounds in a gel or cream formulation are used in this experiment. Placebo contains the same gel or cream ingredients without the active compound.
  • Oral Formulation Capsules or tablets each containing 100-600 mg of the active compound 3-(aryisulfonyl)propanemtriies are used in this example. Placebo capsules or tablets do not contain the active compound.
  • Patients with painful osteoarthritis of the knee controlled by a stable dose of standard NSAID therapy for at least 2 months, discontinue use of the NSAIDs for a 7-day washout period. Patients are then randomized in a 1 : 1 : 1 ratio (1% active gel, 5% active gel, placebo). A total of up to 150 patients are enrolled and treated for 14 days with follow-up at 14, 21, and 28 days.
  • the active gel or placebo is applied to the affected knee 3 times a day for 14 days for a total of 42 treatments given every 4 - 6 hours while awake.
  • the capsules or tablets are orally administered to patients 1-4 times a day for 14 days.
  • NSAIDs may be restarted after the Day 14 visit.
  • the primary clinical activity parameters are the measurement of pain at the site of application, as quantified by Pain on Movement assessment (100-mm VAS) and the Western Ontario and McMaster University (WOMAC) index (100-mm VAS or 5-point Likert scale).
  • Pain on Movement assessment 100-mm VAS
  • WOMAC Western Ontario and McMaster University index
  • the effect of treatment on swelling, tenderness and inflammation of the knee is recorded, also the time to red uction or eradication of pain after treatment is recorded.
  • the primary clinical activity endpoints are:
  • the secondary clinical activity endpoints are:
  • Topical Formulation 3-(Arylsulfonyi)propanetiitriles are prepared as a gel formulation according to Example 3 or as a cream formulation according to Example 4. Active compounds in a gel or cream formulation are used in this experiment. Placebo contains the same gel or cream ingredients without the active compound.
  • Oral Formulation Capsules or tablets each containing 100-800 mg of the active compound 3-(arylsulfbnyl)propanern ⁇ riles are used in this example. Placebo capsules or tablets do not contain the active compound.
  • the active gel or placebo is applied twice a day to affected areas of the body for 12 weeks.
  • the capsules or tablets are orally administered to patients 1-4 times a day for 12 weeks.
  • the treatment results are evaluated at 2 week intervals until week 12 and then at 4 weeks after discontinuation of the study medication.
  • Safety is evaluated by general history and physical signs, laboratory testing for hematology, serum chemistry, and urinalysis, and by evaluations of local application site tolerabiiity parameters of erythema, scaling, dryness, stinging/burning utilizing a rating scale of "0" (None) to "3" (Severe).
  • Topical Formulation 3-(Arylsulfonyl)propaneriitriles are prepared as a gel formulation according to Example 3 or as a cream formulation according to Example 4. Active compounds in a gel or cream formulation are used in this experiment. Placebo contains the same gel or cream ingredients without the active compound.
  • Oral Formulation Capsules or tablets each containing 100-800 mg of the active compound 3-(aryisulfonyl)propanemtri.ies are used in this example. Placebo capsules or tablets do not contain the active compound.
  • Patients are randomized in a 1 : 1 ratio (active gel, placebo). A total of 200 patients are enrolled and treated.
  • the active gel or placebo is applied twice a day to affected areas of the body for 12 weeks.
  • the capsules or tablets are orally administered to patients 1 -4 times a day for 12 weeks.
  • the treatment results are evaluated at 2 week intervals until week 12 and then at 4 weeks after discontinuation of the study medication.
  • Safety is evaluated by general history and physical signs, laboratory testing for hematology, semm chemistry, and urinalysis, and by evaluations of local application site tolerability parameters of erythema, scaling, dryness, stinging/burning utilizing a rating scale of "0" (None) to "3" (Severe).
  • Topical Formulation 3 ⁇ (Arylsulfonyl)propanenitriles are prepared as a gel formulation according to Example 3 or as a cream formulation according to Example 4. Active compounds in a gel or cream formulation are used in this experiment. Placebo contains the same gel or cream ingredients without the active compound.
  • Oral Formulation Capsules or tablets each containing 100-800 mg of the active compound 3-(ar ⁇ ' isuifonyl)piOpanenitriies are used in this example. Placebo capsules or tablets do not contain the active compound.
  • the active gel or placebo is applied twice a day to affected areas of the body for 12 weeks.
  • the capsules or tablets are orally administered to patients 1-4 times a day for 12 weeks.
  • the treatment results are evaluated at 2 week intervals until week 12 and then at 4 weeks after discontinuation of the study medication.
  • Safety is evaluated by general history and physical signs, laboratory testing for hematology, serum chemistry, and urinalysis, and by evaluations of local application site tolerabiiity parameters of erythema, scaling, dryness, stinging/burning utilizing a rating scale of "0" (None) to "3" (Severe).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une composition pharmaceutique contenant un excipient pharmaceutiquement acceptable et un composé d'oméga-(arylsulfonyl)alkylnitrile ou un sel pharmaceutiquement acceptable de celui-ci. L'invention concerne également une méthode de traitement de l'inflammation, des troubles inflammatoires ou de la douleur, par administration d'un composé d'oméga-(arylsulfonyl)alkylnitrile ou d'un sel ou solvate pharmaceutiquement acceptable de celui-ci à un patient nécessitant un tel traitement.
PCT/US2014/067597 2013-11-27 2014-11-26 Composition pharmaceutique contenant un composé d'oméga-(arylsulfonyl)alkylnitrile WO2015081188A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361909762P 2013-11-27 2013-11-27
US61/909,762 2013-11-27

Publications (1)

Publication Number Publication Date
WO2015081188A1 true WO2015081188A1 (fr) 2015-06-04

Family

ID=53199631

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/067597 WO2015081188A1 (fr) 2013-11-27 2014-11-26 Composition pharmaceutique contenant un composé d'oméga-(arylsulfonyl)alkylnitrile

Country Status (1)

Country Link
WO (1) WO2015081188A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4395371A (en) * 1980-10-31 1983-07-26 Bayer Aktiengesellschaft Process for the preparation of 2-halogeno-3-sulphonyl-acrylonitriles
US20100041702A1 (en) * 2007-03-30 2010-02-18 Henricus Jacobus Maria Gijsen Benzimidazole cannabinoid agonists
US20100221336A1 (en) * 2007-02-14 2010-09-02 Logical Therapeutics, Inc. Method of treating arthritis, pain or inflammation with naproxen 2(methanesulfonyl)ethyl ester and a proton pump inhibitor
US20100240756A1 (en) * 2009-03-18 2010-09-23 St Laurent Joseph P Compounds for treating inflammation and pain
US20130172410A1 (en) * 2010-12-15 2013-07-04 Olatec Industries Llc 3-methanesulfonylpropionitrile for treating inflammation and pain
US20130324601A1 (en) * 2012-06-05 2013-12-05 Olatec Industries Llc Pharmaceutical composition for treating inflammation and pain

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4395371A (en) * 1980-10-31 1983-07-26 Bayer Aktiengesellschaft Process for the preparation of 2-halogeno-3-sulphonyl-acrylonitriles
US20100221336A1 (en) * 2007-02-14 2010-09-02 Logical Therapeutics, Inc. Method of treating arthritis, pain or inflammation with naproxen 2(methanesulfonyl)ethyl ester and a proton pump inhibitor
US20100041702A1 (en) * 2007-03-30 2010-02-18 Henricus Jacobus Maria Gijsen Benzimidazole cannabinoid agonists
US20100240756A1 (en) * 2009-03-18 2010-09-23 St Laurent Joseph P Compounds for treating inflammation and pain
US20130172410A1 (en) * 2010-12-15 2013-07-04 Olatec Industries Llc 3-methanesulfonylpropionitrile for treating inflammation and pain
US20130324601A1 (en) * 2012-06-05 2013-12-05 Olatec Industries Llc Pharmaceutical composition for treating inflammation and pain

Similar Documents

Publication Publication Date Title
US20230372279A1 (en) Pharmaceutical composition for treating inflammation and pain
US10441555B2 (en) Pharmaceutical composition
US9889111B2 (en) Pharmaceutical composition comprising omega-(arylsulfonyl)alkylnitrile
EP2854785B1 (fr) Composition pharmaceutique pour traiter l'inflammation et la douleur
US9763909B2 (en) Methods for treating inflammation and pain
US10143675B2 (en) Pharmaceutical composition for treating inflammation and pain
EP2861228B1 (fr) Composés destinés au traitement de l'inflammation et de la douleur
WO2015081188A1 (fr) Composition pharmaceutique contenant un composé d'oméga-(arylsulfonyl)alkylnitrile

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14866696

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14866696

Country of ref document: EP

Kind code of ref document: A1